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In the past several years, the concept of tissue-selective nuclear receptor ligands has emerged.This concept
has come to fruition with estrogens, with the successful marketing of drugs such as raloxifene.The discovery
of raloxifene and other selective estrogen receptor modulators (SERMs) has raised the possibility of generating
selective compounds for other pathways, including androgens (that is, selective androgen receptor modulators,
or SARMs).
Received August 25th, 2003; Accepted September 17th, 2003; Published September 27th, 2003  | Abbreviations: BPH: benign prostatic hyperplasia;
CAB: combined androgen blockade; DHT: dihydrotestosterone; GnRH: gonadotropin-releasing hormone; SARM: selective androgen receptor
modulator; SERM: selective estrogen receptor modulator | Copyright © 2003, Allan and Sui.This is an open-access article distributed under the terms
of the Creative Commons Non-Commercial Attribution License, which permits unrestricted non-commercial use distribution and reproduction in any
medium, provided the original work is properly cited.
Cite this article: Nuclear Receptor Signaling (2003) 1, e009
Pharmacology of Androgens
Androgens control sexual function in the male and are
central to the anabolic processes that underlie the
development of male sexual and physiological
characteristics [Mooradian et al., 1987]. Serum androgen
levels are low prior to puberty and climb exponentially
during adolescence in the male, leading to the enhanced
muscle growth and lean body mass typical of the gender.
In the mature adult they range from 600 to 700 ng/dL. As
men age, androgen levels decline during the so-called
andropause, reaching 450 to 500 ng/dL in their seventies
and eighties [Flynn and Hellstrom, 2001]. Concomitantly,
lean body mass decreases and older men are frailer, with
a greater tendency to falls and bone fractures.
Testosterone (T), acting via its more potent natural
metabolite, dihydrotestosterone (DHT), stimulates
maturation of the prostate during sexual development.
DHT is produced from T by 5-α-reduction, and it binds to
the androgen receptor with about five times greater affinity
than T.The enzyme 5-α-reductase is expressed
tissue-specifically, most prominently in prostate and in
hair follicles.This has been taken advantage of
pharmacologically, with the generation of specific
inhibitors of the enzyme for the treatment of
androgen-dependent disorders. For example, finasteride
is a 5-α-reductase inhibitor that prevents local synthesis
of DHT and is used to treat alopecia.T also has important
physiological effects that are independent of DHT,
including anabolic effects on muscle, maintenance of
testicular function, and inhibition of pituitary gonadotropin
secretion.
Prostate maturation results in the production of prostatic
secretions that form a component of semen, and thus it
is essential for normal fertility. DHT has proliferative
effects on the epithelial compartment of the immature
prostate. Removal of circulating androgens by testicular
or medical castration in humans and rodents results in
apoptosis of prostatic cells and shrinkage of the prostate.
Administration of T to castrated or immature rodents
stimulates prostate growth.
The stimulatory effect of androgens on the prostate
throughout adulthood is often thought to be primarily
responsible for the increased risk of prostate cancer after
the age of 40, although there is no direct proof of this.
Nevertheless, localized and early stage metastatic
prostate cancers are readily treatable by surgery and
combined androgen blockade (CAB). CAB typically
consists of treatment with a gonadotropin-releasing
hormone (GnRH) agonist (such as leuprolide), to shut
down physiological sex steroid synthesis (surgical
castration, or orchidectomy, has the same result); and
an androgen antagonist (such as flutamide or
bicalutamide), to shut down androgen-responsive
pathways. Androgen antagonists have been approved in
the US only for CAB of advanced prostate cancer. CAB
is an expensive therapy and men experience hot flushes
and bone loss due to the depletion of anabolic steroids.
Recently, monotherapy with androgen antagonists has
shown to be as effective as CAB in preventing disease
recurrence [See et al., 2002], and some European
regulatory authorities have approved the use of
bicalutamide for this purpose. However, both currently
used androgen antagonists, flutamide (Eulexin) and
bicalutamide (Casodex), cause breast tenderness and
gynecomastia, which limit their use for monotherapy.
These side effects are due to the propensity of the
compounds to raise serum estrogen levels, which in turn
is due to antagonism of normal feedback inhibition by
testicular androgens at the pituitary.With feedback
inhibition blunted, T synthesis continues, serum T levels
rise, and the excess is aromatized into estrogen [McLeod
and Iversen, 2000].
Benign prostatic hyperplasia (BPH) is a common condition
in middle-aged and older men.The stromal compartment
of the prostate grows larger and obstructs urethral flow,
resulting in difficulty in urination.The etiology of BPH is
poorly understood, but the condition can be treated with
inhibitors of DHT formation (finasteride) or with adrenergic
antagonists. Androgen antagonists are also effective
[Stone and Clejan, 1991], but they are not used due to
their side effects on the male breast.
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they appear to maintain normal secretory activity and hair
growth. Excess androgens can cause acne and excessive
hair growth on the body or face. Facial hair (hirsutism) is
a common symptom of hyperandrogenism in women. In
the scalp, where androgens have a different mechanism
of action, excessive androgen levels cause male-pattern
baldness (alopecia). As mentioned above, the
5-α-reductase inhibitor finasteride is used to treat hair
loss.
Figure 1. Non steroidal SARMs 1, Flutamide; 2, Nilutamide; 3,
Bicalutamide
Testosterone and DHT act via the androgen receptor
(AR), which is a member of the nuclear receptor
superfamily. Binding of an agonist ligand to the receptor
induces conformational changes that result in binding of
the receptor-ligand complex to DNA elements adjacent
to target genes in the genome, followed by changes in
gene expression.These gene expression changes lead
to cellular effects including increases in proliferation and
metabolic activity. Androgen antagonists bind to the
receptor, preventing binding of the natural steroid, but do
not produce the correct receptor conformational change.
Thus, the classic view of receptor-antagonist complexes
is that they fail to elicit normal changes in gene
expression, disrupting androgen-signaling pathways.The
androgen receptor ligand-binding domain has been
crystallized [Matias et al., 2000; Sack et al., 2001], and
it has the typical helical sandwich structure found in other
nuclear receptors.
Figure 2. 2 quinolone and coumarins See text for more details.
In the past several years, the concept of tissue-selective
nuclear receptor ligands has emerged.This concept has
come to fruition with estrogens, with the successful
marketing of drugs such as raloxifene. Raloxifene is an
estrogen antagonist in some estrogen-responsive tissues
(breast and uterus), and an agonist in others (bone).
While the molecular mechanism of action of these
selective estrogen receptor modulators (SERMs) is not
understood, a commonly accepted hypothesis is that
tissue-specific coregulators interact with the steroid
receptor-ligand complexes to modulate their activities in
different ways [Heinlein and Chang, 2002].The discovery
of SERMs has raised the possibility of generating
selective compounds for other pathways, including
androgens (that is, selective androgen receptor
modulators, or SARMs) [Zhi and Martinborough, 2001].
For example, a compound that is an antagonist at the
prostate, but an agonist or weak antagonist at the
pituitary, would have an improved side effect profile over
currently marketed androgen antagonists. Similarly, a
compound that is a strong agonist on muscle, but an
antagonist or weak agonist on prostate could be used to
treat muscle-wasting conditions and age-related frailty,
with a reduced concern for the potential to stimulate
nascent or undetected prostate cancer.
There are four marketed androgen antagonists.Three
are non-steroidal and the fourth (cyproterone) is a steroid
with mixed progestational and androgen antagonist
activities. Of the non-steroids, bicalutamide is currently
the biggest seller, probably due to its long half-life relative
to flutamide, which facilitates once-per-day dosing.
However, flutamide has recently come on the market as
a generic in the United States, which is likely to
significantly impact the future sales of bicalutamide here.
Bicalutamide itself will come off patent in 2008.
Nilutamide’s patent has also expired, but it was always
a poor third to its competitors in terms of side effects and
clinical use, and has not been developed as a generic
compound.
There is a large body of literature supporting their efficacy
in animal models of alopecia [Pan et al., 1998; Sintov et
al., 2000] and in clinical trials treating alopecia
[Diamanti-Kandarakis, 1999], hirsutism [Muderris et al.,
2002;Venturoli et al., 1999;Venturoli et al., 2001] and
acne [Carmina and Lobo, 2002]. A new androgen
antagonist, RU 58841, is in phase II clinical trials in
Europe for the topical treatment of acne and alopecia. As
mentioned above, androgen antagonists also have clinical
efficacy in BPH [Stone and Clejan, 1991].
To our knowledge, there are no non-steroidal androgens
other than RU 58841 in clinical development. A number
of companies, including Bristol Myers Squibb, Ligand
Pharmaceuticals, GTx Technologies and Karo Bio have
internal SARM research programs.The next section will
review new classes of non-steroidal androgen receptor
ligands that are in the public domain.
New Non-Steroidal Androgen Receptor
Ligands
Some progress has been made in identifying new
structural classes of non-steroidal SARMs since the
launch of flutamide (Figure 1, Structure 1), nilutamide
(Figure 1, Structure 2) and bicalutamide (Figure 1,
Structure 3). Among many structures explored, the
following three series have received the most attention:
2-quinolone and coumarins (Figure 2, Series 4),
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derivatives (Figure 4, Series 6).
2-quinolones
The structures of compounds 4a to 4c represent the
2-quinolones (Figure 2). Compounds 4a and 4b are potent
AR antagonists while 4c is an agonist. As frequently seen
in modulators of other steroid receptors such as the
progesterone receptor, small structural changes can lead
to the reversal of agonistic and antagonistic activity. Both
4a and 4b bind to AR in the nanomolar range, with Kis of
26 nM and 21 nM, respectively. Compound 4a seems
more potent and more efficacious in a CV-1 cell functional
assay (4a: 74% efficacy, 27 nM antagonist potency; 4b:
39% efficacy, 34 nM antagonist potency). In addition, 4b
showed some agonist activity in the same cells (39%
efficacy, 125 nM potency). However, in castrated
immature male rats, 4b demonstrated better efficacy as
an antagonist. It inhibited testosterone-induced increases
in prostate weight and seminal vesicle weight (4a: ED50
[prostate] = 18 mg/kg, ED50 [seminal vesicle] = 19 mg/kg;
4b: ED50 [prostate] = 3.1 mg/kg, ED50 [seminal vesicle]
= 7.5 mg/kg), and was orally active [Edwards et al., 2000].
Compound 4c binds to AR with similar affinity (Ki = 17
nM), but showed very good efficacy as an agonist in CV-1
cell functional assays (EC50 = 4 nM). In intact mature
male rats, compound 4a did not raise serum levels of
luteinizing hormone or testosterone, at 20 mg/kg or 40
mg/kg by the oral route.This was in contrast to flutamide
and bicalutamide, which raised the levels of these
hormones two- to eight-fold at these doses [Hamann et
al., 1999].Thus, compound 4a may have an advantage
over current androgen antagonists because of its reduced
potential for side effects in prostate cancer patients.
Figure 3. Phthalimide analogs See text for more details
Phthalamides
Phthalamides (Figure 3) such as 5a were identified as
androgens antagonists with more potency than flutamide
[Miyachi et al., 1997]. Recently, several series of
compounds containing an imide moiety were reported as
SARMs. For example, compound 5b was as potent as
bicalutamide in a CWR22 human prostate cancer
xenograft model [Salvati et al., 2002].
Bicalutamides
Bicalutamide derivatives (Figure 4) continue to receive
attention as SARMs. One of the compounds from this
series, GTx-007, showed an agonist effect in increasing
the weight of the levator ani muscles of castrated male
rats. It had a reduced stimulatory effect on prostate and
seminal vesicles. In addition, the compound did not
suppress luteinizing hormone and follicle stimulating
hormone levels [Dalton et al., 2002].
Figure 4. Bicalutamide derivatives See text for more details
Conclusion
Androgen receptor antagonists have found therapeutic
use in the treatment of androgen-responsive prostate
cancer for over two decades.This use will continue for
the foreseeable future, but therapeutic regimens may
change. In particular, androgen antagonist monotherapy,
rather than CAB or antagonists in combination with
orchidectomy, will likely see increased use, due to its
relatively fewer negative effects on quality of life.
Androgen antagonists will be approved for new clinical
uses, including the treatment of hirsutism in women,
alopecia in men and acne in both sexes. New SARM
antagonists with improved tissue specificity, such as with
reduced effects on the hypogonadal axis, will emerge for
prostate cancer monotherapy, as well as for skin
indications. It is possible that SARM antagonists will find
use in BPH, provided that they have sufficient efficacy.
New laboratory tools, such as the availability of crystal
structures of the receptor for rational drug design, will
facilitate the discovery of new SARMs.
A promising area of research is on the development of
SARM agonists for increasing lean body mass and muscle
strength in hypogonadal men and in cancer and
immunodeficient patients. Ultimately, SARM agonists
may be used to counteract the frailty associated with
aging. As well as being extremely safe overall, such drugs
will have to stimulate muscle strength without increasing
the risk of prostate cancer.Their abuse potential will also
be a factor impacting approval and marketing.
Nevertheless, it is possible to see a day when
tissue-specific androgens of many flavors will be of great
medical benefit.
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